Drugs that target dynamic microtubules: A new molecular perspective

Medicinal Research Reviews

Volumn 31, Issue 3, 2011, Pages 443-481

  Stanton, Richard A ^a   Gernert, Kim M ^b   Nettles, James H ^b   Aneja, Ritu ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drugs; Microtubules; Tubulin binding

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE; COLCHICINE; CRYPTOPHYCIN DERIVATIVE; CURACIN A; DICTYOSTATIN; DISCODERMOLIDE; DOCETAXEL; DOLASTATIN 10; DOLASTATIN 15; EPOTHILONE A; EPOTHILONE B; GRISEOFULVIN; HALICHONDRIN B; IXABEPILONE; LAULIMALIDE; MAYTANSINE; NAVELBINE; PACLITAXEL; PELORUSIDE; PHOMOPSIN A; RHIZOXIN; ROTENONE; SANGUINARINE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE; VINFLUNINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RESISTANCE; CONFORMATIONAL TRANSITION; DIARRHEA; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; FATIGUE; HUMAN; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; OVARY TUMOR; POLYMERIZATION; PROSTATE CANCER; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MICROTUBULES; PHARMACEUTICAL PREPARATIONS;

EID: 79953299183     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20242     Document Type: Article

References (223)

1. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001;30:397-420.
2. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-296.
3. Giannakakou P, Sackett D, Fojo T. Tubulin/microtubules: Still a promising target for new chemotherapeutic agents. J Natl Cancer Inst 2000;92:182-183.
4. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
5. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-450.
6. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
7. Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: Where do we stand? Drug Resist Updat 2006;9:74-86.
8. Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr Pharm Des 2001;7:1213-1228.
9. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000;49:217-225.
10. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998;95:1601-1606.
11. Heidemann S. Microtubules, leukemia, and cough syrup. Blood 2006;107:2216-2217.
12. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5:773-785.
13. Weisenberg RC, Borisy GG, Taylor EW. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 1968;7:4466-4479.
14. Gould RR, Borisy GG. The pericentriolar material in Chinese hamster ovary cells nucleates microtubule formation. J Cell Biol 1977;73:601-615.
15. Mitchison T, Kirschner M. Microtubule assembly nucleated by isolated centrosomes. Nature 1984;312:232-237.
16. Mitchison T, Kirschner M. Dynamic instability of microtubule growth. Nature 1984;312:237-242.
17. Brinkley BR. Microtubule organizing centers. Annu Rev Cell Biol 1985;1:145-172.
18. Walker RA, O'Brien ET, Pryer NK, Soboeiro MF, Voter WA, Erickson HP, Salmon ED. Dynamic instability of individual microtubules analyzed by video light microscopy: Rate constants and transition frequencies. J Cell Biol 1988;107:1437-1448.
19. Valiron O, Caudron N, Job D. Microtubule dynamics. Cell Mol Life Sci 2001;58:2069-2084.
20. Cassimeris L. Regulation of microtubule dynamic instability. Cell Motil Cytoskeleton 1993;26:275-281.
21. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997;13:83-117.
22. Cassimeris LU, Walker RA, Pryer NK, Salmon ED. Dynamic instability of microtubules. Bioessays 1987;7:149-154.
23. Margolis RL, Wilson L. Microtubule treadmilling: What goes around comes around. Bioessays 1998;20:830-836.
24. Erickson HP, O'Brien ET. Microtubule dynamic instability and GTP hydrolysis. Annu Rev Biophys Biomol Struct 1992;21:145-166.
25. Warner FD, Satir P. The substructure of ciliary microtubules. J Cell Sci 1973;12:313-326.
26. Nogales E, Wang HW, Niederstrasser H. Tubulin rings: Which way do they curve? Curr Opin Struct Biol 2003;13:256-261.
27. Nogales E, Wang HW. Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. Curr Opin Struct Biol 2006;16:221-229.
28. Margolis RL, Wilson L. Opposite end assembly and disassembly of microtubules at steady state in vitro. Cell 1978;13:1-8.
29. McIntosh JR, Grishchuk EL, West RR. Chromosome-microtubule interactions during mitosis. Annu Rev Cell Dev Biol 2002;18:193-219.
30. Farrell KW, Jordan MA, Miller HP, Wilson L. Phase dynamics at microtubule ends: The coexistence of microtubule length changes and treadmilling. J Cell Biol 1987;104:1035-1046.
31. Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: Correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7:2912-2922.
32. Lewis SA, Gilmartin ME, Hall JL, Cowan NJ. Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. J Mol Biol 1985;182:11-20.
33. Villasante A, Wang D, Dobner P, Dolph P, Lewis SA, Cowan NJ. Six mouse alpha-tubulin mRNAs encode five distinct isotypes: Testis-specific expression of two sister genes. Mol Cell Biol 1986;6:2409-2419.
34. Pape M, Schnieder T, von Samson-Himmelstjerna G. Investigation of diversity and isotypes of the beta-tubulin cDNA in several small strongyle (Cyathostominae) species. J Parasitol 2002;88:673-677.
35. Arai K, Shibutani M, Matsuda H. Distribution of the class II beta-tubulin in developmental and adult rat tissues. Cell Motil Cytoskeleton 2002;52:174-182.
36. McKean PG, Vaughan S, Gull K. The extended tubulin superfamily. J Cell Sci 2001;114:2723-2733.
37. Saxton WM, Stemple DL, Leslie RJ, Salmon ED, Zavortink M, McIntosh JR. Tubulin dynamics in cultured mammalian cells. J Cell Biol 1984;99:2175-2186.
38. Hayden JH, Bowser SS, Rieder CL. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: Direct visualization in live newt lung cells. J Cell Biol 1990;111:1039-1045.
39. Piehl M, Tulu US, Wadsworth P, Cassimeris L. Centrosome maturation: Measurement of microtubule nucleation throughout the cell cycle by using GFP-tagged EB1. Proc Natl Acad Sci USA 2004;101:1584-1588.
40. Inoue S, Sato H. Cell motility by labile association of molecules. The nature of mitotic spindle fibers and their role in chromosome movement. J Gen Physiol 1967;50:Suppl:259-292.
41. Hyman AA, Karsenti E. Morphogenetic properties of microtubules and mitotic spindle assembly. Cell 1996;84:401-410.
42. Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 1992;3:1141-1154.
43. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell 1995;6:1887-1902.
44. Rodionov VI, Gyoeva FK, Kashina AS, Kuznetsov SA, Gelfand VI. Microtubule-associated proteins and microtubule-based translocators have different binding sites on tubulin molecule. J Biol Chem 1990;265:5702-5707.
45. Ookata K, Hisanaga S, Bulinski JC, Murofushi H, Aizawa H, Itoh TJ, Hotani H, Okumura E, Tachibana K, Kishimoto T. Cyclin B interaction with microtubule-associated protein 4 (MAP4) targets p34cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics. J Cell Biol 1995;128:849-862.
46. McNally FJ. Modulation of microtubule dynamics during the cell cycle. Curr Opin Cell Biol 1996;8:23-29.
47. Mandelkow E, Mandelkow EM. Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995;7:72-81.
48. Masson D, Kreis TE. Binding of E-MAP-115 to microtubules is regulated by cell cycle-dependent phosphorylation. J Cell Biol 1995;131:1015-1024.
49. Ookata K, Hisanaga S, Sugita M, Okuyama A, Murofushi H, Kitazawa H, Chari S, Bulinski JC, Kishimoto T. MAP4 is the in vivo substrate for CDC2 kinase in HeLa cells: Identification of an M-phase specific and a cell cycle-independent phosphorylation site in MAP4. Biochemistry 1997;36:15873-15883.
50. Pryer NK, Walker RA, Skeen VP, Bourns BD, Soboeiro MF, Salmon ED. Brain microtubule-associated proteins modulate microtubule dynamic instability in vitro. Real-time observations using video microscopy. J Cell Sci 1992;103:965-976.
51. Noetzel TL, Drechsel DN, Hyman AA, Kinoshita K. A comparison of the ability of XMAP215 and tau to inhibit the microtubule destabilizing activity of XKCM1. Philos Trans R Soc Lond B Biol Sci 2005;360:591-594.
52. Qiang L, Yu W, Andreadis A, Luo M, Baas PW. Tau protects microtubules in the axon from severing by katanin. J Neurosci 2006;26:3120-3129.
53. Schuyler SC, Pellman D. Microtubule "plus-end-tracking proteins": The end is just the beginning. Cell 2001;105:421-424.
54. Gundersen GG, Gomes ER, Wen Y. Cortical control of microtubule stability and polarization. Curr Opin Cell Biol 2004;16:106-112.
55. Kodama A, Karakesisoglou I, Wong E, Vaezi A, Fuchs E. ACF7: An essential integrator of microtubule dynamics. Cell 2003;115:343-354.
56. Mimori-Kiyosue Y, Grigoriev I, Lansbergen G, Sasaki H, Matsui C, Severin F, Galjart N, Grosveld F, Vorobjev I, Tsukita S, Akhmanova A. CLASP1 and CLASP2 bind to EB1 and regulate microtubule plus-end dynamics at the cell cortex. J Cell Biol 2005;168:141-153.
57. Komarova YA, Akhmanova AS, Kojima S, Galjart N, Borisy GG. Cytoplasmic linker proteins promote microtubule rescue in vivo. J Cell Biol 2002;159:589-599.
58. Komarova Y, De Groot CO, Grigoriev I, Gouveia SM, Munteanu EL, Schober JM, Honnappa S, Buey RM, Hoogenraad CC, Dogterom M, Borisy GG, Steinmetz MO, Akhmanova A. Mammalian end binding proteins control persistent microtubule growth. J Cell Biol 2009;184:691-706.
59. Vaughan KT. TIP maker and TIP marker; EB1 as a master controller of microtubule plus ends. J Cell Biol 2005;171:197-200.
60. Akhmanova A, Steinmetz MO. Tracking the ends: A dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008;9:309-322.
61. Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K, Hirohashi S. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics 2005;5:1411-1422.
62. Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T, Oshimura M. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005;5:3205-3213.
63. Wang Y, Zhou X, Zhu H, Liu S, Zhou C, Zhang G, Xue L, Lu N, Quan L, Bai J, Zhan Q, Xu N. Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene 2005;24:6637-6645.
64. Dong X, Liu F, Sun L, Liu M, Li D, Su D, Zhu Z, Dong JT, Fu L, Zhou J. Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol 2009;220:361-369.
65. Gard DL, Kirschner MW. A microtubule-associated protein from Xenopus eggs that specifically promotes assembly at the plus-end. J Cell Biol 1987;105:2203-2215.
66. Vasquez RJ, Gard DL, Cassimeris L. XMAP from Xenopus eggs promotes rapid plus end assembly of microtubules and rapid microtubule polymer turnover. J Cell Biol 1994;127:985-993.
67. Tournebize R, Popov A, Kinoshita K, Ashford AJ, Rybina S, Pozniakovsky A, Mayer TU, Walczak CE, Karsenti E, Hyman AA. Control of microtubule dynamics by the antagonistic activities of XMAP215 and XKCM1 in Xenopus egg extracts. Nat Cell Biol 2000;2:13-19.
68. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007;13:2849-2854.
69. Desai A, Verma S, Mitchison TJ, Walczak CE. Kin I kinesins are microtubule-destabilizing enzymes. Cell 1999;96:69-78.
70. Newton CN, Wagenbach M, Ovechkina Y, Wordeman L, Wilson L. MCAK, a Kin I kinesin, increases the catastrophe frequency of steady-state HeLa cell microtubules in an ATP-dependent manner in vitro. FEBS Lett 2004;572:80-84.
71. Hunter AW, Caplow M, Coy DL, Hancock WO, Diez S, Wordeman L, Howard J. The kinesin-related protein MCAK is a microtubule depolymerase that forms an ATP-hydrolyzing complex at microtubule ends. Mol Cell 2003;11:445-457.
72. Moores CA, Yu M, Guo J, Beraud C, Sakowicz R, Milligan RA. A mechanism for microtubule depolymerization by KinI kinesins. Mol Cell 2002;9:903-909.
73. Ganem NJ, Compton DA. The KinI kinesin Kif2a is required for bipolar spindle assembly through a functional relationship with MCAK. J Cell Biol 2004;166:473-478.
74. Manning AL, Ganem NJ, Bakhoum SF, Wagenbach M, Wordeman L, Compton DA. The kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. Mol Biol Cell 2007;18:2970-2979.
75. Rizk RS, Bohannon KP, Wetzel LA, Powers J, Shaw SL, Walczak CE. MCAK and paclitaxel have differential effects on spindle microtubule organization and dynamics. Mol Biol Cell 2009;20:1639-1651.
76. Gupta ML, Jr., Carvalho P, Roof DM, Pellman D. Plus end-specific depolymerase activity of Kip3, a kinesin-8 protein, explains its role in positioning the yeast mitotic spindle. Nat Cell Biol 2006;8:913-923.
77. Varga V, Helenius J, Tanaka K, Hyman AA, Tanaka TU, Howard J. Yeast kinesin-8 depolymerizes microtubules in a length-dependent manner. Nat Cell Biol 2006;8:957-962.
78. Mayr MI, Hummer S, Bormann J, Gruner T, Adio S, Woehlke G, Mayer TU. The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. Curr Biol 2007;17:488-498.
79. Cai S, Weaver LN, Ems-McClung SC, Walczak CE. Kinesin-14 family proteins HSET/XCTK2 control spindle length by cross-linking and sliding microtubules. Mol Biol Cell 2009;20:1348-1359.
80. Jourdain L, Curmi P, Sobel A, Pantaloni D, Carlier MF. Stathmin: A tubulin-sequestering protein which forms a ternary T2S complex with two tubulin molecules. Biochemistry 1997;36:10817-10821.
81. Steinmetz MO. Structure and thermodynamics of the tubulin-stathmin interaction. J Struct Biol 2007;158:137-147.
82. Curmi PA, Andersen SS, Lachkar S, Gavet O, Karsenti E, Knossow M, Sobel A. The stathmin/tubulin interaction in vitro. J Biol Chem 1997;272:25029-25036.
83. Steinmetz MO, Kammerer RA, Jahnke W, Goldie KN, Lustig A, van Oostrum J. Op18/stathmin caps a kinked protofilament-like tubulin tetramer. EMBO J 2000;19:572-580.
84. Manna T, Thrower D, Miller HP, Curmi P, Wilson L. Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro. J Biol Chem 2006;281:2071-2078.
85. Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci 1999;112:3713-3722.
86. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.
87. Dorleans A, Gigant B, Ravelli RB, Mailliet P, Mikol V, Knossow M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci USA 2009;106:13775-13779.
88. Goldstein LS, Yang Z. Microtubule-based transport systems in neurons: The roles of kinesins and dyneins. Annu Rev Neurosci 2000;23:39-71.
89. Goldstein LS, Philp AV. The road less traveled: Emerging principles of kinesin motor utilization. Annu Rev Cell Dev Biol 1999;15:141-183.
90. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998;279:519-526.
91. Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 2003;24:361-365.
92. Panda D, Jordan MA, Chu KC, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 1996;271:29807-29812.
93. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947-959.
94. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000;16:89-111.
95. Elie-Caille C, Severin F, Helenius J, Howard J, Muller DJ, Hyman AA. Straight GDP-tubulin protofilaments form in the presence of taxol. Curr Biol 2007;17:1765-1770.
96. Rao S, He L, Chakravarty S, Ojima I, Orr GA, Horwitz SB. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J Biol Chem 1999;274:37990-37994.
97. Morris PG, Fornier MN. Microtubule active agents: Beyond the taxane frontier. Clin Cancer Res 2008;14:7167-7172.
98. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981;256:10435-10441.
99. Hamel E, del Campo AA, Lowe MC, Lin CM. Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem 1981;256:11887-11894.
100. Thompson WC, Wilson L, Purich DL. Taxol induces microtubule assembly at low temperature. Cell Motil 1981;1:445-454.
101. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J. Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 1981;78:5608-5612.
102. Nogales E, Wolf SG, Khan IA, Luduena RF, Downing KH. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 1995;375:424-427.
103. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424.
104. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008;9:168-175.
105. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996;49:560-563.
106. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-2333.
107. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997;272:2534-2541.
108. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000;1470:M79-M91.
109. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
110. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-1437.
111. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roche HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217.
112. Liu J, Towle MJ, Cheng H, Saxton P, Reardon C, Wu J, Murphy EA, Kuznetsov G, Johannes CW, Tremblay MR, Zhao H, Pesant M, Fang FG, Vermeulen MW, Gallagher BM, Jr., Littlefield BA. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 2007;27:1509-1518.
113. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH. Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharmacol 2007;4:269-280.
114. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ. Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 2006;70:1555-1564.
115. Madiraju C, Edler MC, Hamel E, Raccor BS, Balachandran R, Zhu G, Giuliano KA, Vogt A, Shin Y, Fournier JH, Fukui Y, Bruckner AM, Curran DP, Day BW. Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin. Biochemistry 2005;44:15053-15063.
116. Giannakakou P, Fojo T. Discodermolide: Just another microtubule-stabilizing agent? No! A lesson in synergy. Clin Cancer Res 2000;6:1613-1615.
117. Chen SM, Meng LH, Ding J. New microtubule-inhibiting anticancer agents. Expert Opin Investig Drugs 2010;19:329-343.
118. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009;35:255-261.
119. Cutts JH, Beer CT, Noble RL. Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res 1960;20:1023-1031.
120. Rai SS, Wolff J. Localization of the vinblastine-binding site on beta-tubulin. J Biol Chem 1996;271:14707-14711.
121. Toso RJ, Jordan MA, Farrell KW, Matsumoto B, Wilson L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 1993;32:1285-1293.
122. Takanari H, Yosida T, Morita J, Izutsu K, Ito T. Instability of pleomorphic tubulin paracrystals artificially induced by Vinca alkaloids in tissue-cultured cells. Biol Cell 1990;70:83-90.
123. Wilson L, Jordan MA, Morse A, Margolis RL. Interaction of vinblastine with steady-state microtubules in vitro. J Mol Biol 1982;159:125-149.
124. Warfield RK, Bouck GB. Microtubule-macrotubule transitions: Intermediates after exposure to the mitotic inhibitor vinblastine. Science 1974;186:1219-1221.
125. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 1998;55:635-648.
126. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-515.
127. Gupta S, Bhattacharyya B. Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 2003;253:41-47.
128. Kupchan SM, Komoda Y, Court WA, Thomas GJ, Smith RM, Karim A, Gilmore CJ, Haltiwanger RC, Bryan RF. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972;94:1354-1356.
129. Hamel E. Antimitotic natural products and their interactions with tubulin. Med Res Rev 1996;16:207-231.
130. Fellous A, Luduena RF, Prasad V, Jordan MA, Anderson W, Ohayon R, Smith PT. Effects of Tau and MAP2 on the interaction of maytansine with tubulin: Inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. Cancer Res 1985;45:5004-5010.
131. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141-17149.
132. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG. Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 1976;72:47-54.
133. Bhattacharyya B, Wolff J. Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 1977;75:159-162.
134. Iwasaki S, Kobayashi H, Furukawa J, Namikoshi M, Okuda S, Sato Z, Matsuda I, Noda T. Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis. J Antibiot (Tokyo) 1984;37:354-362.
135. Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, Sato Y. Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys Acta 1987;926:215-223.
136. Wolpert-Defilippes MK, Adamson RH, Cysyk RL, Johns DG. Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide. Biochem Pharmacol 1975;24:751-754.
137. Hamel E. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55:31-51.
138. Koiso Y, Li Y, Iwasaki S, Hanaoka K, Kobayashi T, Sonoda R, Fujita Y, Yaegashi H, Sato Z. Ustiloxins, antimitotic cyclic peptides from false smut balls on rice panicles caused by Ustilaginoidea virens. J Antibiot (Tokyo) 1994;47:765-773.
139. Luduena RF, Roach MC, Prasad V, Lacey E. Effect of phomopsin A on the alkylation of tubulin. Biochem Pharmacol 1990;39:1603-1608.
140. Pettit GR, Herald CL, Boyd MR, Leet JE, Dufresne C, Doubek DL, Schmidt JM, Cerny RL, Hooper JN, Rutzler KC. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991;34:3339-3340.
141. Cormier A, Marchand M, Ravelli RB, Knossow M, Gigant B. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep 2008;9:1101-1106.
142. Boukari H, Sackett DL, Schuck P, Nossal RJ. Single-walled tubulin ring polymers. Biopolymers 2007;86:424-436.
143. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990;39:1941-1949.
144. Bai R, Roach MC, Jayaram SK, Barkoczy J, Pettit GR, Luduena RF, Hamel E. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993;45:1503-1515.
145. Luduena RF, Roach MC, Prasad V, Pettit GR. Interaction of dolastatin 10 with bovine brain tubulin. Biochem Pharmacol 1992;43:539-543.
146. Li Y, Kobayashi H, Hashimoto Y, Shirai R, Hirata A, Hayashi K, Hamada Y, Shioiri T, Iwasaki S. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: Competitive inhibition of rhizoxin and phomopsin A binding. Chem Biol Interact 1994;93:175-183.
147. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 1992;43:2637-2645.
148. Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 1993;44:757-766.
149. Bai R, Taylor GF, Cichacz ZA, Herald CL, Kepler JA, Pettit GR, Hamel E. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995;34:9714-9721.
150. Smith CD, Zhang X. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem 1996;271:6192-6198.
151. Smith CD, Zhang X, Mooberry SL, Patterson GM, Moore RE. Cryptophycin: A new antimicrotubule agent active against drug-resistant cells. Cancer Res 1994;54:3779-3784.
152. Rej R, Nguyen D, Go B, Fortin S, Lavallee JF. Total synthesis of cryptophycins and their 16-(3-Phenylacryloyl) derivatives. J Org Chem 1996;61:6289-6295.
153. Eissler S, Bogner T, Nahrwold M, Sewald N. Efficient synthesis of cryptophycin-52 and novel para-alkoxymethyl unit A analogues. Chemistry 2009;15:11273-11287.
154. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003;39:197-199.
155. Panda D, DeLuca K, Williams D, Jordan MA, Wilson L. Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc Natl Acad Sci USA 1998;95:9313-9318.
156. Panda D, Singh JP, Wilson L. Suppression of microtubule dynamics by LY290181. A potential mechanism for its antiproliferative action. J Biol Chem 1997;272:7681-7687.
157. Bai R, Schwartz RE, Kepler JA, Pettit GR, Hamel E. Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res 1996;56:4398-4406.
158. Downing KH, Nogales E. Crystallographic structure of tubulin: Implications for dynamics and drug binding. Cell Struct Funct 1999;24:269-275.
159. Downing KH, Nogales E. New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J 1998;27:431-436.
160. Garland DL. Kinetics and mechanism of colchicine binding to tubulin: Evidence for ligand-induced conformational change. Biochemistry 1978;17:4266-4272.
161. Peterson JR, Mitchison TJ. Small molecules, big impact: A history of chemical inhibitors and the cytoskeleton. Chem Biol 2002;9:1275-1285.
162. Borisy GG, Taylor EW. The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. J Cell Biol 1967;34:535-548.
163. Borisy GG, Taylor EW. The mechanism of action of colchicine. Binding of colchincine-3H to cellular protein. J Cell Biol 1967;34:525-533.
164. Brossi A, Yeh HJ, Chrzanowska M, Wolff J, Hamel E, Lin CM, Quin F, Suffness M, Silverton J. Colchicine and its analogues: Recent findings. Med Res Rev 1988;8:77-94.
165. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008;28:155-183.
166. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991;51:377-401.
167. Nogales E, Whittaker M, Milligan RA, Downing KH. High-resolution model of the microtubule. Cell 1999;96:79-88.
168. Wilson C, Hargreaves RB. Inhibition of the pharmacological effects of endothelin. Prog Med Chem 1994;31:371-410.
169. Skoufias DA, Wilson L. Mechanism of inhibition of microtubule polymerization by colchicine: Inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 1992;31:738-746.
170. Sullivan KF, Cleveland DW. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci USA 1986;83:4327-4331.
171. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 1988;4:687-716.
172. Banerjee A, Roach MC, Trcka P, Luduena RF. Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. J Biol Chem 1992;267:5625-5630.
173. Ray K, Bhattacharyya B, Biswas BB. Role of B-ring of colchicine in its binding to tubulin. J Biol Chem 1981;256:6241-6244.
174. Banerjee A, Barnes LD, Luduena RF. The role of the B-ring of colchicine in the stability of the colchicine-tubulin complex. Biochim Biophys Acta 1987;913:138-144.
175. Engelborghs Y, Fitzgerald TJ. Kinetic and thermodynamic aspects of tubulin-ligand interactions: Binding of the colchicine analog 2-methoxy-5-(2', 3', 4'-trimethoxyphenyl) tropone. Ann N Y Acad Sci 1986;466:709-717.
176. Engelborghs Y, Fitzgerald TJ. A fluorescence stopped flow study of the competition and displacement kinetics of podophyllotoxin and the colchicine analog 2-methoxy-5-(2', 3', 4'-trimethoxyphenyl) tropone on tubulin. J Biol Chem 1987;262:5204-5209.
177. Banerjee A, Luduena RF. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 1991;266:1689-1691.
178. Banerjee A, D'Hoore A, Engelborghs Y. Interaction of desacetamidocolchicine, a fast binding analogue of colchicine with isotypically pure tubulin dimers alpha beta II, alpha beta III, and alpha beta IV. J Biol Chem 1994;269:10324-10329.
179. Hamel E, Lin CM. Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem Pharmacol 1983;32:3864-3867.
180. Cirla A, Mann J. Combretastatins: From natural products to drug discovery. Nat Prod Rep 2003;20:558-564.
181. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
182. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-211.
183. Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2002;2:143-148.
184. Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res 1998;58:4510-4514.
185. Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, Van Der Schaft DW, Van Esch AM, Joosten-Achjanie SR, Lambin P, Landuyt W, Griffioen AW. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int J Cancer 2003;105:20-25.
186. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
187. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-6991.
188. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-3968.
189. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 1983;103:282-288.
190. Desbene S, Giorgi-Renault S. Drugs that inhibit tubulin polymerization: The particular case of podophyllotoxin and analogues. Curr Med Chem Anticancer Agents 2002;2:71-90.
191. Sukumaran K, Kuttan R. Screening of 11 ferns for cytotoxic and antitumor potential with special reference to Pityrogramma calomelanos. J Ethnopharmacol 1991;34:93-96.
192. Beutler JA, Cardellina JH, 2nd, Gray GN, Prather TR, Shoemaker RH, Boyd MR, Lin CM, Hamel E, Cragg GM. Two new cytotoxic chalcones from Calythropsis aurea. J Nat Prod 1993;56:1718-1722.
193. Orjala J, Wright AD, Behrends H, Folkers G, Sticher O, Ruegger H, Rali T. Cytotoxic and antibacterial dihydrochalcones from Piper aduncum. J Nat Prod 1994;57:18-26.
194. Alias Y, Awang K, Hadi AH, Thoison O, Sevenet T, Pais M. An antimitotic and cytotoxic chalcone from Fissistigma lanuginosum. J Nat Prod 1995;58:1160-1166.
195. Peyrot V, Leynadier D, Sarrazin M, Briand C, Menendez M, Laynez J, Andreu JM. Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: Equilibrium studies. Biochemistry 1992;31:11125-11132.
196. Smith DB, Ewen C, Mackintosh J, Fox BW, Thatcher N, Scarffe JH, Vezin R, Crowther D. A phase I and pharmacokinetic study of amphethinile. Br J Cancer 1988;57:623-627.
197. Ducki S, Mackenzie G, Greedy B, Armitage S, Chabert JF, Bennett E, Nettles J, Snyder JP, Lawrence NJ. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 2: Structure-based discovery of alpha-aryl chalcones. Bioorg Med Chem 2009;17:7711-7722.
198. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-325.
199. Lawrence NJ, McGown AT, Ducki S, Hadfield JA. The interaction of chalcones with tubulin. Anticancer Drug Des 2000;15:135-141.
200. Ducki S, Mackenzie G, Lawrence NJ, Snyder JP. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly. J Med Chem 2005;48:457-465.
201. Segal MS, Glodstein MM, Attinger EO. The use of noscapine (narcotine) as an antitussive agent. Dis Chest 1957;32:305-309.
202. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol 1982;22:535-539.
203. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, Van Meir EG, Glass JD, Joshi HC, Archer DR. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004;10:5187-5201.
204. Landen JW, Lang R, McMahon SJ, Rusan NM, Yvon AM, Adams AW, Sorcinelli MD, Campbell R, Bonaccorsi P, Ansel JC, Archer DR, Wadsworth P, Armstrong CA, Joshi HC. Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 2002;62:4109-4114.
205. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002;277:17200-17208.
206. Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, Joshi HC. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002;277:39777-39785.
207. Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007;67:3862-3870.
208. Ye K, Zhou J, Landen JW, Bradbury EM, Joshi HC. Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis. J Biol Chem 2001;276:46697-46700.
209. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2006;107:2486-2492.
210. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, Nettles JH, Zhou B, Gupta M, Panda D, Chandra R, Joshi HC. Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res 2006;66:3782-3791.
211. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol 2006;69:1801-1809.
212. Aneja R, Vangapandu SN, Joshi HC. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog. Bioorg Med Chem 2006;14:8352-8358.
213. Aneja R, Vangapandu SN, Lopus M, Viswesarappa VG, Dhiman N, Verma A, Chandra R, Panda D, Joshi HC. Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 2006;72:415-426.
214. Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: Apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther 2006;5:2366-2377.
215. Aneja R, Asress S, Dhiman N, Awasthi A, Rida PC, Arora SK, Zhou J, Glass JD, Joshi HC. Non-toxic melanoma therapy by a novel tubulin-binding agent. Int J Cancer 2010;126:256-265.
216. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, Joshi HC. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003;63:799-807.
217. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer 2010;46:1668-1678.
218. Karna P, Rida PC, Pannu V, Gupta KK, Dalton WB, Joshi H, Yang VW, Zhou J, Aneja R. A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering. Cell Death Differ 2010, in press.
219. Karna P, Sharp SM, Yates C, Prakash S, Aneja R. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer 2009;8:93.
220. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, Joshi HC. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007;60:831-839.
221. Lowe J, Li H, Downing KH, Nogales E. Refined structure of alpha beta-tubulin at 3.5A resolution. J Mol Biol 2001;313:1045-1057.
222. Li H, DeRosier DJ, Nicholson WV, Nogales E, Downing KH. Microtubule structure at 8A resolution. Structure 2002;10:1317-1328.
223. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. Structural basis for the regulation of tubulin by vinblastine. Nature 2005;435:519-522.